Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593110 · ClinicalTrials.gov registry record · NA
Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 114
- Enrollment target
NCT02593110 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 114 participants.
The verdict
NCT02593110, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 114 participants
- Enrollment target
Study Summary
The TELEX trial will establish whether telmisartan alone improves walking performance in people with peripheral artery disease (PAD). The TELEX trial will also determine whether telmisartan plus supervised exercise improves walking performance more than either therapy alone. TELEX is a randomized controlled clinical trial (2 x 2 factorial design) of 112 participants with PAD randomized to one of four arms: Group A: telmisartan + supervised exercise therapy; Group B: telmisartan + a "no exercise" control group; Group C: placebo + supervised exercise therapy; and Group D: placebo + a "no exercise" control group.
Interventions
- DRUG Placebo
- DRUG Telmisartan
- BEHAVIORAL Supervised Treadmill Exercise Therapy
- OTHER "No exercise" control group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-01-04 |
| Est. Completion | 2022-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593110
The ClinicalTrials.gov registry entry for NCT02593110 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02593110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02593110 about?
NCT02593110 is a clinical study titled "Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease". The TELEX trial will establish whether telmisartan alone improves walking performance in people with peripheral artery disease (PAD). The TELEX trial will also determine whether telmisartan plus supervised exercise improves walking performance more than either therapy alone. TELEX is a randomized co...
What is the current status of trial NCT02593110?
This trial is currently completed. It is a NA study. The enrollment target is 114 participants. The study started on 2016-01-04. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT02593110?
The interventions under investigation include: Placebo (DRUG), Telmisartan (DRUG), Supervised Treadmill Exercise Therapy (BEHAVIORAL), "No exercise" control group (OTHER).
Who is sponsoring clinical trial NCT02593110?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.